Cabaletta Bio to Present at H.C. Wainwright BioConnect Investor Conference
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA), a trailblazer in engineered T cell therapies for autoimmune diseases, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. …
Cabaletta Bio to Present at H.C. Wainwright BioConnect Investor Conference Read More